星点设计–效应面法优化眼局部应用雷公藤红素纳米结构脂质载体处方
Preparation and Formulation Optimization of Loaded Celastrol Nanostructure Lipid Carriers for Topical Ocular Application
DOI: 10.12677/HJO.2019.84025, PDF,   
作者: 郭 莹：新乡医学院河南省人民医院，河南 郑州；河南省眼科研究所，河南 郑州；梁 珍, 王敬博, 张俊杰*：河南省眼科研究所，河南 郑州；张 振：2河南省眼科研究所，河南 郑州
关键词: 雷公藤红素；纳米结构脂质载体；星点设计-效应面法；粒径；包封率；载药量；微乳法；Celastrol； Nano-Structure Lipid Carrier； Central Composite Design-Response Surface Methodology； Encapsulation Rate； Drug Loading Rate
摘要: 目的：采用星点设计–效应面法(CCD-RSM)优化应用于眼局部应用雷公藤红素纳米结构脂质载体(CEL-NLC)处方。方法: 通过测定雷公藤红素在各种脂质的溶解度，筛选出溶解度较好的脂质，采用微乳法制备CEL-NLC，分别以药物/脂质用量比(X1)、表面活性剂/助表面活性剂用量比(X2)为考察对象，以粒径(Y1)、包封率(Y2)和载药量(Y3)为考察指标，经效应面法预测最佳处方，并验证最佳处方。结果：根据CCD-RSM优化得出最佳处方为雷公藤红素40 mg，棕榈酸0.09 g，油酸0.18 g，吐温-80 4.34 g，甘油2.16 g。按最优处方制备的CEL-NLC包封率为(75.28 ± 3.44)%，载药量为(0.45 ± 0.02)%；粒径为(18.66 ± 2.63) nm，多分散指数(PDI)为0.39 ± 0.03。实际值与预测值偏差均小于5%。结论：采用CCD-RSM优化的CEL-NLC处方，包封率高，粒径小，稳定性好，方法可靠，可进一步用于眼局部应用雷公藤红素的后续研究。
Abstract: Objective: The central composite design-response surface methodology (CCD-RSM) was used to optimize the application of tricorne nanostructured lipid carrier (CEL-NLC) in the local application of eyes. Methods: The lipid with the best solubility was screened out by determining the solubility of celastrol in different lipids. CEL-NLC was prepared by microemulsion technique. Quality of solid lipid (X1), quality of liquid lipid (X2), surfactant/cosurfactant (X3) as objects of investigation, while particle size (Y1), encapsulation efficiency (Y2) and drug loadings rate (Y3) as dependent variables, the optimal prescription was obtained by CCD-RSM and verified subsequently. Results: The best prescription of CEL-NLC was Celastrol 0.04 g, palmitic acid 0.09 g, oleic acid 0.18g, tween-80 4.34 g and Glycerine 2.16 g. The encapsulation efficiency was (75.28 ± 3.44)%; the drug loading rate was (0.45 ± 0.02)%; the particle size was (18.66 ± 2.63) nm. The PDI was 0.39 ± 0.03. The deviation between the measured and predicted values was less than 5%. Conclusion: The optimized CEL-NLC obtained by CCD-RSM has high encapsulation efficiency, small particle size and good stability, which can be further used in the follow-up study of local application of Celastrol in eyes.
文章引用：郭莹, 梁珍, 张振, 王敬博, 张俊杰. 星点设计–效应面法优化眼局部应用雷公藤红素纳米结构脂质载体处方[J]. 眼科学, 2019, 8(4): 160-168. https://doi.org/10.12677/HJO.2019.84025

参考文献

[1] 袁菱, 周蕾, 陈彦, 等. 雷公藤红素纳米结构脂质载体的制备及其理化性质考察[J]. 中成药, 2013, 35(9): 2023-2027.
[2] 李萍, 黄萌萌, 刘玉萍, 等. 雷公藤红素-薏苡仁油微乳的制备及其体外抗肿瘤活性评价[J]. 中国实验方剂学志, 2017, 23(6): 1-6.
[3] Sanna, V., Chamcheu, J.C., et al. (2015) Nanoencapsulation of Natural Triterpenoid Celastrol for Prostate Cancer Treatment. International Journal of Nanomedicine, 10, 6835-6846.
[Google Scholar] [CrossRef] 
[4] 袁菱, 周蕾, 陈彦, 等. 雷公藤红素纳米结构脂质载体的制备及其体外透皮研究[J]. 中成药, 2012, 43(8): 1514-1518.
[5] Fu, T., Yi, J.L., Lv, S.Y. and Zhang, B. (2016) Ocular Amphotericin B Delivery by Chitosan Modified Nanostructured Lipid Carriers for Fungal Keratitis Targeted Therapy. Journal of Liposome Research, 27, 228-233.
[Google Scholar] [CrossRef] [PubMed]
[6] Li, Z.R., Li, J.G., Zhu, L., et al. (2016) Celastrolnanomicelles Attenuate Cytokine Secretion in macrophages and Inhibit Macrophage-Induced Corneal Neovascularization in Rats. International Journal of Nanomedicine, 11, 6135-6148.
[Google Scholar] [CrossRef] 
[7] 周维, 李小芳, 向志芸, 等. 星点设计-效应面优化黄芩苷自微乳化制剂的处方[J]. 中药与临床, 2016, 7(1): 27-30+36.
[8] 刘碧林, 石明芯, 朱照静, 等. 星点设计-效应面法优化姜黄素正负离子纳米结构脂质载体处方[J]. 中草药, 2016, 47(19): 3401-3406.
[9] 杨龙, 陈凌云, 魏刚, 等. 眼用脂质纳米制剂的研究进展[J]. 中国医药工业杂志, 2016, 47(12): 1592-1599.
[10] 高珊珊, 李宁, 田宝成, 等. 星点设计-响应面法优化氯诺昔康纳米结构脂质载体处方[J]. 中国药房, 2017, 28(28): 3980-3983.
[11] Sánchez-López, E., Espina, M., Doktorovova, S., Souto, E.B. and García, M.L. (2016) Lipid Nanoparticles (SLN, NLC): Overcoming the Anatomical and Physiological Barriers of the Eye-Part II-Ocular Drug-Loaded Lipid Nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 110, 58-69.
[Google Scholar] [CrossRef] [PubMed]
[12] Üstündag-Okur, N., Homan Gökçe, E., Inci, D., et al. (2014) Preparation and in Vitro-in Vivo Evaluation of Ofloxacin Loaded Ophthalmic Nano Structured Lipid Carriers Modified with Chitosan Oligosaccharide Lactate for the Treatment of Bacterial Keratitis. European Journal of Pharmaceutical Sciences, 63, 204-215.
[Google Scholar] [CrossRef] [PubMed]
[13] Mo, Z., Ban, J.F., Zhang, Y., Du, Y., et al. (2018) Nanostructured Lipid Carriers-Based Thermosensitive Eye Drops Forenhanced, Sustained Delivery of Dexamethasone. Nanomedicine, 13, 1239-1253.
[Google Scholar] [CrossRef] [PubMed]
[14] 田霞, 范云周, 孙媛, 等. 星点设计-效应面法优化蒿甲醚自微乳释药系统[J]. 国际药学研究杂志, 2016, 43(5): 966-970.
[15] 陈蕾, 战争尧, 李姝影. 星点设计-效应面法优化吴茱萸碱脂质体的处方[J]. 中国药师, 2017, 20(1): 77-81+90.
[16] Hejri, A., Khosravi, A., Gharanjig, K. and Hejazi, M. (2013) Optimisation of the Formulation of B-Carotene Loaded Nanostructured Lipid Carriers Prepared by Solvent Diffusion Method. Food Chemistry, 141, 117-123.
[17] Sarangi, B., Jana, U., Sahoo, J., Prasad Mohanta, G. and Kumar Manna, P. (2018) Systematic Approach for the Formulation and Optimization of Atorvastatin Loaded Solid Lipid NANOAPARTICLES Using Response Surface Methodology. Biomedical Microdevices, 20, 53.
[Google Scholar] [CrossRef] [PubMed]
[18] Shen, J., Deng, Y.P., Jin, X.F., et al. (2010) Thiolated Nanostructured Lipid Carriers as a Potential Ocular Drug Delivery System for Cyclosporine A: Improving in Vivo Ocular Distribution. International Journal of Pharmaceutics, 402, 248-253.
[Google Scholar] [CrossRef] [PubMed]
[19] Sandri, G., Motta, S., Bonferoni, M.C., et al. (2017) Chitosan-Coupled Solid Lipid Nanoparticles: Tuning Nanostructure and Mucoadhesion. European Journal of Pharmaceutics and Biopharmaceutics, 110, 13-18.

为你推荐